# Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma

> **NCT05831891** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 39 (actual)

## Conditions studied

- Non-clear Renal Cell Carcinoma

## Interventions

- **DRUG:** Fruquintinib combined with Serplulimab

## Key facts

- **NCT ID:** NCT05831891
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05831891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05831891, "Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT05831891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*